Tony Arulanandam

Company: Cytovia Therapeutics

Job title: Senior Vice President & Head of Preclinical Research


CYT-303 is a Novel Mutispecific NKp46 NK Cell Engager Against GPC3 Expressing HCC Tumors that Mediates Potent Tumor Killing and Reverses NK Cell Dysfunction in the Tumor Microenvironment 9:00 am

CYT-303 NK cell engager mediates potent HCC tumor killing via NK cell redirected killing, antibody-dependent macrophage phagocytosis (ADCP), and complement-mediated cytotoxicity (CDC) CYT-303 reverses NK cell dysfunction observed in the HCC tumor microenvironment in serial killing and hypoxia and TGF-beta-mediated immunosuppressive states CYT-303 shows potent dose-dependent anti-tumor activity in humanized HCC subcutaneous tumor models correlating…Read more

day: Day One

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.